Who Paid My Doc
Mitul Patel
General Practice East Patchogue, NY Medical Doctor
NPI 1285615120 CMS profile 1254012
250 Patchogue Yaphank Rd, Suites # 7, East Patchogue, NY 11772
General payments
$671
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mitul Patel of East Patchogue, NY is reported in the CMS Open Payments database as having received $671 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 74th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $15 | 1 | |
| 2024 | General | $257 | 2 | |
| 2023 | General | $195 | 6 | |
| 2021 | General | $51 | 2 | |
| 2020 | General | $22 | 1 | |
| 2019 | General | $131 | 3 |
Beside peers
- Mitul Patel
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Mitul Patel were reported at $15. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Mitul Patel | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $131 | $107 | $37–$285 | $163 |
| 2020 | $22 | $75 | $25–$213 | $114 |
| 2021 | $51 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $195 | $106 | $34–$276 | $160 |
| 2024 | $257 | $114 | $39–$290 | $164 |
| 2025 | $15 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 117 drugsPart D claims
7,940
Drug cost
$311,471
Branded share of claims
13.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 158 | $77,374 | |
| Xarelto Rivaroxaban | Brand | 35 | $18,646 | |
| Januvia Sitagliptin Phosphate | Brand | 52 | $18,429 | |
| Cinacalcet Hcl | Generic | 15 | $15,338 | |
| Farxiga Dapagliflozin Propanediol | Brand | 20 | $15,111 | |
| Ozempic Semaglutide | Brand | 16 | $14,170 | |
| Rybelsus Semaglutide | Brand | 13 | $13,210 | |
| Myrbetriq Mirabegron | Brand | 22 | $9,995 | |
| Entresto Sacubitril/Valsartan | Brand | 13 | $8,967 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 12 | $8,459 |
The 10 drugs with the highest cost, of 117 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$493,797
Medicare patients
231
Services billed
7,659
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 60% | |
| Alzheimer's or dementia | 58% | |
| Diabetes | 56% | |
| Ischemic heart disease | 54% | |
| Heart failure | 45% | |
| Chronic kidney disease | 42% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Influenza vaccine, trivalent, 0.5 ml dosage 90658 | Office | 82 | 82 | $1,756 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 51 | 387 | $375 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in New York
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.